DFTX
HOLD / NEUTRALMeanRevComposite
51.20
Technical
100.00
Fundamental
34.90
Rank
—
Price
48.45
Hurst
0.15
As of
Jul 10, 2026
Daily
Definium Therapeutics, Inc.
HealthcareBiotechnologyDefinium Therapeutics is a biopharmaceutical firm focused on developing treatments for neurological and psychiatric conditions. The company's primary experimental drugs include DT120, currently in late-stage testing for anxiety and depression disorders, and DT402, an investigational compound in earlier trials for autism spectrum disorder. Headquartered in New York, the company was previously known as Mind Medicine before rebranding in early 2026.
Market cap
$5.2B
P/E (trailing)
—
P/E (forward)
-20.57
PEG ratio
—
Dividend yield
—
Beta
2.24
52w range
8.77 – 49.70
Return on equity
-64.09%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 37.85 (+299.3%) · range 9.04–48.45
Cycle position
38/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 40 · WEAK SETUP · exit proximity 15
Conviction
46/ 100 · maturity 14%
VScore.0916
Buildup.3070
EMA entry setup.3840
Fundamentals.2335
Volume profile
POC
44.16
Price vs POC
-14.3%
Overhead supply
54%
Runway
+13.2%
Value area 23.64–49.70 · 54% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| trader-sentiment | 0.769 | Sep 14, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.98% | -1.98% | mature |
| 40d | -19.08% | -1.89% | mature |